• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于结肠或双相释放的薄膜包衣片的γ闪烁扫描评估

Gamma scintigraphic evaluation of film-coated tablets intended for colonic or biphasic release.

作者信息

Ofori-Kwakye Kwabena, Fell John T, Sharma Harbans L, Smith Anne-Marie

机构信息

School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester M13 9PL, UK.

出版信息

Int J Pharm. 2004 Feb 11;270(1-2):307-13. doi: 10.1016/j.ijpharm.2003.11.009.

DOI:10.1016/j.ijpharm.2003.11.009
PMID:14726145
Abstract

The gastrointestinal transit and in vivo drug release behaviour of a film-coated tablet formulation was investigated in five healthy human subjects using the technique of gamma scintigraphy. The film coating system consisted of a mixture of pectin, chitosan and HPMC in a ratio of 6:1:0.37 applied to 750 mg cores at a coat weight gain of 9%. The estimated mean values of the gastric emptying time (62+/-17 min), small intestinal transit time (219+/-53 min), ileocaecal junction lag time (79+/-30 min) and the colon arrival time (345+/-33 min), were similar to published values for the transit of similar sized tablets in humans. The amount of radioactive tracer released from the labelled tablets was minimal when the tablets were in the stomach and the small intestine. There was increased release of radioactivity when the tablets were in the colon due to increased degradation of the film coatings by pectinolytic enzymes resident in the colon. The pectin/chitosan/HPMC film coating system thus acts as a colonic delivery system.

摘要

采用γ闪烁扫描技术,在5名健康人体受试者中研究了薄膜包衣片剂制剂的胃肠道转运及体内药物释放行为。薄膜包衣系统由果胶、壳聚糖和羟丙基甲基纤维素按6:1:0.37的比例混合而成,以9%的包衣增重施加于750mg片芯上。胃排空时间(62±17分钟)、小肠转运时间(219±53分钟)、回盲部连接滞后时间(79±30分钟)和结肠到达时间(345±33分钟)的估计平均值与已发表的类似大小片剂在人体中转运的数值相似。当片剂位于胃和小肠中时,从标记片剂中释放的放射性示踪剂数量极少。当片剂位于结肠中时,由于结肠中存在的果胶分解酶使薄膜包衣降解增加,放射性释放增加。因此,果胶/壳聚糖/羟丙基甲基纤维素薄膜包衣系统可作为一种结肠给药系统。

相似文献

1
Gamma scintigraphic evaluation of film-coated tablets intended for colonic or biphasic release.用于结肠或双相释放的薄膜包衣片的γ闪烁扫描评估
Int J Pharm. 2004 Feb 11;270(1-2):307-13. doi: 10.1016/j.ijpharm.2003.11.009.
2
An in vitro investigation into the potential for bimodal drug release from pectin/chitosan/HPMC-coated tablets.关于果胶/壳聚糖/羟丙基甲基纤维素包衣片双模式药物释放潜力的体外研究。
Int J Pharm. 1999 Oct 15;188(1):11-8. doi: 10.1016/s0378-5173(99)00197-0.
3
Selective drug delivery to the colon using pectin:chitosan:hydroxypropyl methylcellulose film coated tablets.使用果胶:壳聚糖:羟丙基甲基纤维素薄膜包衣片将药物选择性递送至结肠。
Int J Pharm. 1999 Oct 5;187(2):251-7. doi: 10.1016/s0378-5173(99)00196-9.
4
Scintigraphic evaluation of colon targeting pectin-HPMC tablets in healthy volunteers.健康志愿者中结肠靶向果胶-羟丙基甲基纤维素片的闪烁扫描评估
Int J Pharm. 2009 Mar 31;370(1-2):144-50. doi: 10.1016/j.ijpharm.2008.12.002. Epub 2008 Dec 7.
5
In vitro evaluation of pectin-HPMC compression coated 5-aminosalicylic acid tablets for colonic delivery.用于结肠给药的果胶-羟丙基甲基纤维素压制包衣5-氨基水杨酸片的体外评价
Eur J Pharm Biopharm. 2002 Jan;53(1):65-73. doi: 10.1016/s0939-6411(01)00225-9.
6
The potential use of mixed films of pectin, chitosan and HPMC for bimodal drug release.果胶、壳聚糖和羟丙基甲基纤维素混合膜用于双峰药物释放的潜在用途。
J Control Release. 1999 Apr 19;58(3):303-10. doi: 10.1016/s0168-3659(98)00168-0.
7
Biphasic drug release from film-coated tablets.薄膜包衣片中的双相药物释放。
Int J Pharm. 2003 Jan 16;250(2):431-40. doi: 10.1016/s0378-5173(02)00578-1.
8
Controlled release of dual drug-loaded hydroxypropyl methylcellulose matrix tablet using drug-containing polymeric coatings.使用含药聚合物包衣对双药负载羟丙基甲基纤维素基质片剂进行控释。
Int J Pharm. 1999 Oct 15;188(1):71-80. doi: 10.1016/s0378-5173(99)00204-5.
9
Characterization of 5-fluorouracil release from hydroxypropylmethylcellulose compression-coated tablets.羟丙基甲基纤维素压制包衣片中5-氟尿嘧啶释放特性的研究
Pharm Dev Technol. 2007;12(2):203-10. doi: 10.1080/10837450601168722.
10
Biphasic drug release: the permeability of films containing pectin, chitosan and HPMC.双相药物释放:含果胶、壳聚糖和羟丙基甲基纤维素的薄膜的渗透性
Int J Pharm. 2001 Sep 11;226(1-2):139-45. doi: 10.1016/s0378-5173(01)00802-x.

引用本文的文献

1
Effect of Source and Degree of Esterification of High Methoxyl Pectin on Oral Colon-Targeted Multiparticulated Delivery of Otilonium Bromide.高甲氧基果胶的来源和酯化程度对溴化奥替溴铵口服结肠靶向多颗粒递送的影响。
ACS Omega. 2025 Aug 4;10(32):36481-36495. doi: 10.1021/acsomega.5c04979. eCollection 2025 Aug 19.
2
In Vitro Evaluation of Cocoa Pod Husk Pectin as a Carrier for Chronodelivery of Hydrocortisone Intended for Adrenal Insufficiency.可可豆荚壳果胶作为用于肾上腺皮质功能不全的氢化可的松定时释放载体的体外评价
J Drug Deliv. 2017;2017:8284025. doi: 10.1155/2017/8284025. Epub 2017 Dec 24.
3
Physicochemical and Antimicrobial Properties of Cocoa Pod Husk Pectin Intended as a Versatile Pharmaceutical Excipient and Nutraceutical.
可可豆荚壳果胶作为多功能药用辅料和营养保健品的物理化学及抗菌特性
J Pharm (Cairo). 2016;2016:7608693. doi: 10.1155/2016/7608693. Epub 2016 Mar 14.
4
Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.开发基于儿科人群的利伐沙班药代动力学模型。
Clin Pharmacokinet. 2014 Jan;53(1):89-102. doi: 10.1007/s40262-013-0090-5.
5
Characterization of soy polysaccharide and its in vitro and in vivo evaluation for application in colon drug delivery.大豆多糖的特性及其在结肠递药系统中的应用的体内外评价。
AAPS PharmSciTech. 2012 Sep;13(3):934-43. doi: 10.1208/s12249-012-9810-7. Epub 2012 Jun 28.
6
Preparation and gamma scintigraphic evaluation of colon specific pellets of ketoprofen prepared by powder layering technology.采用粉末包衣技术制备的结肠定位型酮洛芬微丸的制备及γ闪烁扫描评价。
Daru. 2011;19(1):47-56.
7
Pectin matrix as oral drug delivery vehicle for colon cancer treatment.果胶基质作为口服药物传递载体用于结肠癌治疗。
AAPS PharmSciTech. 2011 Mar;12(1):201-14. doi: 10.1208/s12249-010-9564-z. Epub 2010 Dec 31.
8
Meal-induced acceleration of tablet transit through the human small intestine.进餐引起的片剂在人体小肠内转运加速。
Pharm Res. 2009 Feb;26(2):356-60. doi: 10.1007/s11095-008-9749-2. Epub 2008 Nov 4.
9
Ambroxol Lozenge Bioavailability : Part II - Analysis of Additional Systemic AvailabilityPart I of this article was published in Clin Drug Invest 2003; 23 (4): 273-80.氨溴索口含片的生物利用度:第二部分——额外全身利用度分析 本文第一部分发表于 2003 年《临床药物研究》;23(4):273-80。
Clin Drug Investig. 2004;24(11):681-8. doi: 10.2165/00044011-200424110-00007.
10
Advances in colonic drug delivery.结肠给药的进展。
Drugs. 2005;65(14):1991-2007. doi: 10.2165/00003495-200565140-00006.